Aventis Ketek CAP Resistance Claim Needs Larger Trials, Advisory Cmte. Says
Executive Summary
Aventis Ketek (telithromycin) needs additional studies in more patients with penicillin- and erythromycin-resistant Streptococcus pneumoniae, FDA's Anti-Infectives Advisory Committee said April 26.
You may also be interested in...
Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity
Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains
Aventis Ketek July Launch Will Highlight Targeted Antibacterial Activity
Aventis' promotional message for Ketek will center on the antibiotic's ability to specifically target all pathogens commonly associated with respiratory tract infections without affecting other bacterial strains
Aventis Plans To Launch Genasense, Ketek and Apidra In 2004
The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco